Herrada J, Cabanillas F, Rice L, Manning J, Pugh W
University of Texas M.D. Anderson Cancer Center, Baylor College of Medicine, and Methodist Hospital, Houston 77030, USA.
Ann Intern Med. 1998 Apr 15;128(8):657-62. doi: 10.7326/0003-4819-128-8-199804150-00010.
Castleman disease, an unusual condition of unknown cause consisting of a massive proliferation of lymphoid tissue, remains a clinicopathologic diagnosis. Three histologic variants (hyaline vascular, plasma-cell, and mixed) and two clinical types (localized and multicentric) of Castleman disease have been described.
To analyze the clinical features, management, and outcome of patients with Castleman disease.
Case series.
University referral hospitals.
All patients with Castleman disease who were seen at Texas Medical Center, Houston, Texas, between 1977 and 1995.
Surgical excision for localized disease; surgery, combination chemotherapy, or prednisone for multicentric disease.
Patients were identified according to initial presentation as having localized or multicentric Castleman disease. Patients within each group were further subdivided according to whether they had hyaline vascular, plasma-cell, or mixed disease.
Data from 15 patients were analyzed. All 7 patients with localized disease underwent surgical excision and remain free of disease. The 8 patients with multicentric disease were further subdivided according to initial treatment: Three patients who received combination chemotherapy are currently alive and free of disease; 2 patients treated with prednisone are alive but have needed intermittent maintenance therapy for disease reactivations; and 2 patients treated with surgery only have died, 1 of infectious complications and 1 of non-Hodgkin lymphoma.
Localized and multicentric Castleman disease are different clinical disorders with overlapping histologic features. Localized disease can be cured with surgery, but complete remissions in patients with multicentric disease have been achieved only with chemotherapy or prednisone given at the time of diagnosis.
卡斯特曼病是一种病因不明的罕见疾病,由淋巴组织大量增生构成,仍然是一种临床病理诊断。已描述了卡斯特曼病的三种组织学变型(透明血管型、浆细胞型和混合型)和两种临床类型(局限性和多中心性)。
分析卡斯特曼病患者的临床特征、治疗及预后。
病例系列。
大学转诊医院。
1977年至1995年间在得克萨斯州休斯敦市得克萨斯医学中心就诊的所有卡斯特曼病患者。
局限性疾病行手术切除;多中心性疾病行手术、联合化疗或使用泼尼松治疗。
根据初始表现将患者分为局限性或多中心性卡斯特曼病。每组患者再根据是否患有透明血管型、浆细胞型或混合型疾病进一步细分。
分析了15例患者的数据。所有7例局限性疾病患者均接受了手术切除,且仍无疾病复发。8例多中心性疾病患者根据初始治疗进一步细分:3例接受联合化疗的患者目前存活且无疾病复发;2例接受泼尼松治疗的患者存活,但因疾病复发需要间歇性维持治疗;2例仅接受手术治疗的患者已死亡,1例死于感染并发症,1例死于非霍奇金淋巴瘤。
局限性和多中心性卡斯特曼病是具有重叠组织学特征的不同临床疾病。局限性疾病可通过手术治愈,但多中心性疾病患者仅在诊断时接受化疗或泼尼松治疗才能实现完全缓解。